Tybost: Covers the first $50 per month/$600 per year of co-payments.Įdurant, Intelence, Prezista, and PrezcobixĬovers the first $7,500 per year of co-payments, deductibles, and co-insurance.Ĭovers the first $6,800 per year of co-payments, deductibles, and co-insurance for each of 12 eligible prescriptions. Descovy and Truvada: Covers the first $4,800 per year of co-payments.Įmtriva: Covers the first $300 per month/$3,600 per year of co-payments. Atripla, Complera, Odefsey, and Stribild: Covers the first $6,000 per year of co-payments. Genvoya: Covers the first $7,200 per year of co-payments. Norvir: Covers up to $1,200 a year for co-payments.Įvotaz, Reyataz, and Sustiva: Up to $7,500 annually for co-payments, deductibles, and co-insurance in all commercially-insured plans.Ītripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada, and Tybost Kaletra: Co-payment assistance covers the first $400 per prescription per month. HIV Cost-Sharing Assistance Program (CAP)
Once the form is completed, case managers or individuals then submit the single form to each individual company, reducing the overall amount of paperwork necessary to apply for a patient assistance program. This form combines common information collected on each individual companies form to allow individuals to fill out one form. In 2012, the Department of Health and Human Services (DHHS), along with seven pharmaceutical companies, the National Alliance of State and Territorial AIDS Directors (NASTAD), and community stakeholders developed a common patient assistance program application form that can be used by both providers and patients. An individual is eligible for the HarborPath ADAP waiting list program only if he or she has been deemed eligible for ADAP in his or her state and is verified to be on an ADAP waiting list in that state. HarborPath, a non-profit organization that helps uninsured individuals living with HIV gain access to brand-name prescription medicines at no cost, operates a special patient assistance program for individuals on ADAP waiting lists. Each individual company has different eligibility criteria for application and enrollment in their patient assistance program.
The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.Ĭapitalized product names are trademarks of Janssen Therapeutics, Division of Janssen Products, LP.The bad news is that changes may be on the way for consumers, as some big health insurers no longer allow the amount of the co-pay cards to be applied towards their deductible or out-of-pocket maximum, or steer them towards other cost-containing measures such as step therapy or individual generics that break up an STR.Ī cost-sharing assistance program (CAP) is a program operated by pharmaceutical companies to offer cost-sharing assistance (including deductibles, co-payments and co-insurance) to people with private health insurance to obtain HIV drugs at the pharmacy.Ī patient assistance program (PAP) is a program run through pharmaceutical companies to provide free or low-cost medications to people with low-incomes who do not qualify for any other insurance or assistance programs, such as Medicaid, Medicare, or AIDS Drug Assistance Programs (ADAPs). Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. This information is intended for the use of patients and caregivers in the United States and Puerto Rico only. The ultimate responsibility for patient care resides with a healthcare professional. The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. This site is published by Janssen Therapeutics, Division of Janssen Products, LP., which is solely responsible for its contents.
© Janssen Therapeutics, Division of Janssen Products, LP.